Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

• Ngā kaituhi matua: Hong Xiang (Author), Abigael G. Chan (Author), Ago Ahene (Author), David I. Bellovin (Author), Rong Deng (Author), Amy W. Hsu (Author), Ursula Jeffry (Author), Servando Palencia (Author), Janine Powers (Author), James Zanghi (Author), Helen Collins (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-depe...